NCATS-SM1440
NCATS-SM1440 is a glycolysis inhibitor and metabolic regulator that targets LDHA and LDHB (IC50=0.06 μM and 0.03 μM, respectively). Upon binding to LDHA, NCATS-SM1440 blocks the glycolysis pathway and reduces lactate production. NCATS-SM1440 drives the shift of pyruvate metabolism toward mitochondrial metabolism, effectively disrupting the dependence of cancer cells on aerobic glycolysis. NCATS-SM1440 can be widely used in research related to cancer, Ewing's sarcoma, and other related conditions.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1964516-59-3
- Fòrmula: C30H22F2N4O4S3
- Peso molecular:636.71
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
[1]|
hLDHA 0.06 μM (IC50) |
hLDHB 0.03 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A673 | IC50 |
265 nM
Compound: 42
|
Cytotoxicity against human A673 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
Cytotoxicity against human A673 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
|
[PMID: 32902275] |
| MIA PaCa-2 | IC50 |
268 nM
Compound: 42
|
Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
|
[PMID: 32902275] |
In Vitro
NCATS-SM1440 stabilizes LDHA in cells with an IC50 of 57 nM, depletes NAD+, and fully inhibits glycolysis at elevated concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NCATS-SM1440 (i.v.; p.o.) exhibits favorable pharmacokinetic properties in mice, including 73.8% oral bioavailability, measurable systemic exposure via both intravenous and oral routes, and moderate T1/2 values[2].
NCATS-SM1440 demonstrates significant in vivo antitumor activity in mouse tumor xenografts by inhibiting LDH activity, redirecting tumor cell metabolism, and synergizing with mitochondrial inhibitors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1964516-59-3
-
Peso molecular 636.71
-
Fòrmula C30H22F2N4O4S3
-
SMILES
O=C(C1=CSC(N2N=C(C(CC3=CC=C(S(=O)(N)=O)C(F)=C3)=C2CC4CC4)C5=CC(C#CC6=CC=CS6)=C(F)C=C5)=N1)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Puxeddu M, et al. Metabolism, a Blossoming Target for Small-Molecule Anticancer Drugs. Molecules. 2025;30(17):3457. Published 2025 Aug 22. [Content Brief]
[3]. Masci D, et al. Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy. Molecules. 2024;29(9):2110. Published 2024 May 2. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NCATS-SM1440 Related Classifications
HY-183858 Related Classifications
Powered by Bioz